BioIntelliSense, ACC Join Forces to Advance Remote Cardiac Care; Will Offer BioButton COVID-19 Screening Solution at ACC.21

The ACC and BioIntelliSense, Inc., a continuous health monitoring and clinical intelligence company, have formed a strategic collaboration that combines innovative medical-grade wearable devices and data science to advance remote patient monitoring programs for cardiac care. The ACC will also offer the BioButton COVID-19 Screening Solution to provide an added layer of safety at ACC.21 in Atlanta in May.

The FDA-cleared BioSticker and medical-grade BioButton wearable devices allow for continuous vital sign monitoring of temperature, heart rate and respiratory rate at rest to enable early detection of adverse vital sign trends through its proprietary biosensor technology and advanced analytics. The strategic collaboration will combine ACC's clinical expertise in heart health with BioIntelliSense's effortless user experience and multi-parameter monitoring to make remote cardiac care scalable, reliable and cost effective.

ACC.21 will bring together cardiologists and cardiovascular specialists from around the world to share the newest discoveries in treatment and prevention. The ACC is committed to creating a healthy and safe environment for attendees, exhibitors and staff in line with all current directives and recommendations that will enable attendees to make informed and safe decisions about their attendance. In addition to all CDC recommended COVID-19 safety protocols, ACC.21 conference attendees will have the option to participate in the BioButton COVID-19 Screening Solution for continuous vital sign and symptom monitoring for COVID-like infection. ACC.21 is the first major medical conference to use the BioButton solution.

"The ACC – and the cardiovascular community as a whole – has a long history of advancing innovative solutions to transform cardiovascular care and patient outcomes," said ACC President Athena Poppas, MD, FACC. "We are excited by the opportunity to partner with BioIntelliSense and be on the cutting edge of an innovative technology with real-time health data and feedback."

James Mault, MD, CEO of BioIntelliSense, commented: "We are proud to form a strategic collaboration with the American College of Cardiology to advance virtual care and remote patient monitoring (RPM) programs that can transform cardiac care. Together with the ACC, we can provide the cardiology community with medical-grade monitoring devices, clinically validated algorithms and RPM education that will have a profound impact on routine patient care globally. The inclusion of BioButton COVID-19 Screening Program to the safety measures for the ACC Scientific Session will also serve to provide their cardiovascular professional membership an opportunity to experience the simplicity of virtual care and effortless remote monitoring."

Keywords: Respiratory Rate, Heart Rate, Cost-Benefit Analysis, Specialization, COVID-19, Monitoring, Physiologic, Early Diagnosis, Cardiovascular System, Technology, Intelligence, Biosensing Techniques, Algorithms, Patient Care, Centers for Disease Control and Prevention (U.S.)


< Back to Listings